Connor, Clark & Lunn Investment Management (CC&L)
INZY

Connor, Clark & Lunn Investment Management (CC&L)’s Inozyme Pharma INZY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,832
Closed -$267K – 1521
2024
Q1 		$267K Buy
+34,832
New +$191K ﹤0.01% 1309

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s INZY Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Inozyme Pharma (INZY) in Q2 2024, closing a stake of 34,832 shares — an estimated $267K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in INZY in Q1 2024 and held it in 1 quarter. The position peaked at $267K in Q1 2024. 90 funds tracked by Wall St. Rank hold INZY as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Inozyme Pharma position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 34,832 Inozyme Pharma shares in Q2 2024, an estimated $267K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Inozyme Pharma in Q1 2024 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Inozyme Pharma position peaked at $267K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.